| NCT01234974 | Milton S. Hershey Medical Center | Multiple Myeloma | 2010-12 | PHASE2 |
| NCT04281680 | Helsinki University Central Hospital | Surgical Complications | 2014-07-01 | |
| NCT01582061 | Novartis Pharmaceuticals | Cushing´s Disease | 2011-08-16 | PHASE3 |
| NCT01128192 | Robert R. Henry, MD|Veterans Medical Research Foundation | Hyperglycemia | 2009-08 | PHASE2 |
| NCT01468532 | Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI) | Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer | 2011-10 | PHASE1|PHASE2 |
| NCT02713776 | Hospices Civils de Lyon | Enterostomy | 2016-12-13 | PHASE2 |
| NCT01673646 | Novartis Pharmaceuticals | Acromegaly|Pituitary Gigantism | 2012-10-16 | PHASE2 |
| NCT01915303 | Novartis Pharmaceuticals | Cushings Disease | 2014-03-06 | PHASE2 |
| NCT02310269 | RECORDATI GROUP | Cushings Disease | 2013-03-28 | |
| NCT02835131 | Montefiore Medical Center | Congenital Hyperinsulinism | | |
| NCT00446082 | Novartis Pharmaceuticals | Carcinoid Tumor|Acromegaly | 2006-06 | PHASE1 |
| NCT05928390 | RECORDATI GROUP | Post-Bariatric Hypoglycemia | 2024-01-04 | PHASE2 |
| NCT01283542 | Novartis Pharmaceuticals | Non-functioning Pituitary Adenoma | 2012-11-26 | PHASE2 |
| NCT00929669 | University of Pennsylvania | Gonadotroph Adenomas | 2009-06 | PHASE2 |
| NCT01374451 | Novartis Pharmaceuticals | Islet Cell Tumor | 2011-06 | PHASE2 |
| NCT01253161 | H. Lee Moffitt Cancer Center and Research Institute|Novartis Pharmaceuticals|RECORDATI GROUP | Neuroendocrine Tumors|Carcinoid Tumors | 2011-02-01 | PHASE2 |
| NCT03053284 | Montefiore Medical Center|Novartis Pharmaceuticals | Congenital Hyperinsulinism|Insulinoma|Hyperinsulinism | 2017-04 | PHASE2 |
| NCT02622906 | Robert Benamouzig | Angiodysplasia | 2012-03 | PHASE2 |
| NCT03847207 | Nxera Pharma UK Limited | Healthy | 2019-01-23 | PHASE1 |
| NCT04826432 | Gustave Roussy, Cancer Campus, Grand Paris | Peritoneal Carcinomatosis | 2020-09-03 | PHASE2 |
| NCT00690430 | Novartis Pharmaceuticals | Symptomatic Refractory Resistant Carcinoid Disease | 2008-04 | PHASE3 |
| NCT02749227 | Columbia University | Pituitary Tumor|ACTH-producing Pituitary Tumour | 2017-07-10 | PHASE2 |
| NCT01374906 | Novartis Pharmaceuticals | Cushing´s Disease | 2011-11-04 | PHASE3 |
| NCT01488487 | UNC Lineberger Comprehensive Cancer Center|Novartis Pharmaceuticals | Advanced Adult Hepatocellular Carcinoma | 2011-12 | PHASE2 |
| NCT01652547 | Novartis Pharmaceuticals | Metastatic Melanoma and Merkel Cell Carcinoma | 2012-11 | PHASE1 |
| NCT01620138 | Universidade Federal do Rio de Janeiro | Non-functioning Pituitary Adenomas|Prolactinomas | 2010-03 | PHASE2|PHASE3 |
| NCT00958841 | Novartis Pharmaceuticals | Pancreatic Neoplasm|Pituitary Neoplasm|Nelson Syndrome|Ectopic ACTH Syndrome | 2009-09 | PHASE2 |
| NCT00994110 | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals | Pancreatic Cancer | 2009-10 | PHASE3 |
| NCT00171951 | Novartis Pharmaceuticals | Cushing Disease | 2004-08-13 | PHASE2 |
| NCT06295952 | Memorial Sloan Kettering Cancer Center|RECORDATI GROUP | Prolactin-Producing Pituitary Tumor | 2024-02-27 | PHASE2 |
| NCT02060383 | Novartis Pharmaceuticals | Cushing´s Disease|Acromegaly | 2014-05-23 | PHASE4 |
| NCT00171730 | Novartis Pharmaceuticals | Acromegaly | 2004-08-24 | PHASE2 |
| NCT01252251 | Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals | Uveal Melanoma | 2010-11 | PHASE2 |
| NCT00088595 | Novartis Pharmaceuticals | Carcinoid Tumors | 2004-01 | PHASE2 |
| NCT02215070 | Anthony Sung, MD|Massachusetts General Hospital | Hematological Malignancies | 2015-01-21 | PHASE2 |
| NCT01372618 | NYU Langone Health | Ductal Carcinoma in Situ | 2011-06 | PHASE1|PHASE2 |
| NCT01995734 | Novartis Pharmaceuticals | Acromegaly | | |
| NCT01263353 | Novartis Pharmaceuticals | Gastroenteropancreatic Neuroendocrine Tumor of the Pulmonary ot Gastroenteropancreatic System | 2010-11 | PHASE1 |
| NCT01372644 | NYU Langone Health|United States Department of Defense | Atypical Ductal Breast Hyperplasia|Lobular Carcinoma in Situ (LCIS)|Atypical Lobular Hyperplasia (ALH) of Breast | 2007-11 | PHASE1 |
| NCT01137682 | Novartis Pharmaceuticals | Acromegaly | 2010-07-19 | PHASE3 |
| NCT01356862 | Alliance Pour La Recherche en Cancerologie | Breast Cancer | 2010-09 | PHASE2 |
| NCT02527993 | Zealand University Hospital | Hypoglycemia|Obesity|Surgery | 2015-10 | PHASE4 |
| NCT01417806 | South Florida Veterans Affairs Foundation for Research and Education|Novartis Pharmaceuticals | Small Cell Lung Cancer | 2011-07 | PHASE2 |
| NCT02780882 | Cedars-Sinai Medical Center|Novartis | Ectopic ACTH Syndrome | 2015-12 | PHASE2 |
| NCT03080181 | University of Palermo | Cushing Disease | 2013-05 | PHASE4 |
| NCT02779257 | University of Maryland, Baltimore|Novartis | Gastro-enteropancreatic Neuroendocrine Tumor | 2016-04 | PHASE4 |
| NCT00600886 | Novartis Pharmaceuticals | Acromegaly | 2008-02-11 | PHASE3 |
| NCT07312643 | RECORDATI GROUP|Nuvisan | Pharmacokinetics|Safety | 2025-12-01 | PHASE1 |
| NCT01794793 | RECORDATI GROUP | Cushing´s Disease|Acromegaly|Neuroendocrine Tumors|Pituitary Tumors|Ectopic ACTH Secreting (EAS) Tumors|Dumping Syndrome|Prostate Cancer|Melanoma Negative for bRAF|Melanoma Negative for nRAS | 2013-06-10 | PHASE4 |
| NCT00434148 | Novartis Pharmaceuticals | Cushing´s Disease | 2006-12 | PHASE3 |
| NCT02775227 | Helsinki University Central Hospital | Pancreatic Fistula|Pancreatic Neoplasms | 2016-05 | PHASE4 |
| NCT01364415 | Novartis Pharmaceuticals | Neuroendocrine Tumors | 2011-08 | PHASE1 |
| NCT01895296 | Universitaire Ziekenhuizen KU Leuven | Postoperative Dumping Syndrome | 2008-09 | PHASE2 |
| NCT00088582 | Novartis Pharmaceuticals | Acromegaly | 2004-03 | PHASE2 |
| NCT02668172 | Erasmus Medical Center|Novartis | Acromegaly | 2015-08 | PHASE4 |
| NCT01617733 | Sheffield Teaching Hospitals NHS Foundation Trust|Novartis|The Christie NHS Foundation Trust|Oxford University Hospitals NHS Trust|Barts & The London NHS Trust | Nelson Syndrome | 2011-03 | PHASE2 |
| NCT03514576 | Zealand University Hospital | Hypoglycemia, Reactive | 2018-06-01 | PHASE4 |
| NCT01313559 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University|Novartis Pharmaceuticals | Castrate Resistant Prostate Cancer|Chemotherapy Naive Prostate Cancer|Prostate Cancer | 2011-06 | PHASE2 |
| NCT01670110 | Mayo Clinic | Somatostatin Analogs|Polycystic Liver Disease|Autosomal Dominant Polycystic Kidney Disease|Autosomal Dominant Polycystic Liver Disease | 2012-08 | PHASE2 |
| NCT02354508 | Novartis Pharmaceuticals | Acromegaly | 2015-03-31 | PHASE3 |
| NCT01270321 | Emory University|Novartis | Thyroid Cancer | 2010-11 | PHASE2 |
| NCT00698464 | Novartis Pharmaceuticals | Hepatic Cirrhosis|Alcoholism | 2008-07 | PHASE1 |
| NCT01563354 | Novartis Pharmaceuticals | Neuroendocrine Carcinoma of the Lung and Thymus | 2013-08-16 | PHASE2 |
| NCT01385956 | H. Lee Moffitt Cancer Center and Research Institute|Novartis Pharmaceuticals | Pancreatic Cancer | 2011-06 | PHASE1 |
| NCT01639352 | Lynn Feun | Hepatocellular Carcinoma | 2012-07 | PHASE2 |
| NCT02619617 | Novartis Pharmaceuticals | Cluster Headache - Episodic and Chronic | 2016-10-31 | PHASE2 |
| NCT01646684 | Novartis Pharmaceuticals | Castration Resistant Prostate Cancer | 2013-03-08 | PHASE1 |
| NCT00804336 | Dana-Farber Cancer Institute|Beth Israel Deaconess Medical Center|Brigham and Women´s Hospital|Massachusetts General Hospital|Novartis | Neuroendocrine Tumor|Carcinoid Tumor|Pancreatic Neuroendocrine Tumor | 2008-10 | PHASE1 |
| NCT01329289 | University of Pittsburgh|Novartis | Multiple Myeloma in Relapse|Multiple Myeloma | 2011-12 | PHASE2 |
| NCT02021942 | Prof. Dr. Berthold Schalke|Crolll Gmbh | Primary Inoperable Thymoma|Local Recurrent Thymoma | 2012-03 | PHASE2 |
| NCT01625520 | Federico II University | Medullary Thyroid Cancer | 2012-02 | PHASE2 |
| NCT01637272 | Novartis Pharmaceuticals | Dumping Syndrome | 2013-01-08 | PHASE2 |
| NCT00088608 | Novartis Pharmaceuticals | Cushing´s Syndrome | 2004-04 | PHASE2 |
| NCT01578928 | Novartis Pharmaceuticals | Renal Impairment | 2012-05 | PHASE1 |
| NCT01590199 | Novartis Pharmaceuticals | Neuroendocrine Tumors | 2012-05-18 | PHASE1 |